WO2011093810A2 - Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone - Google Patents

Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone Download PDF

Info

Publication number
WO2011093810A2
WO2011093810A2 PCT/TR2011/000012 TR2011000012W WO2011093810A2 WO 2011093810 A2 WO2011093810 A2 WO 2011093810A2 TR 2011000012 W TR2011000012 W TR 2011000012W WO 2011093810 A2 WO2011093810 A2 WO 2011093810A2
Authority
WO
WIPO (PCT)
Prior art keywords
dry powder
capsule
particle size
mean particle
powder form
Prior art date
Application number
PCT/TR2011/000012
Other languages
English (en)
Other versions
WO2011093810A3 (fr
Inventor
Bilgic Mahmut
Original Assignee
Bilgic Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00619A external-priority patent/TR201000619A2/xx
Priority claimed from TR2010/00730A external-priority patent/TR201000730A2/xx
Application filed by Bilgic Mahmut filed Critical Bilgic Mahmut
Publication of WO2011093810A2 publication Critical patent/WO2011093810A2/fr
Publication of WO2011093810A3 publication Critical patent/WO2011093810A3/fr
Priority to US13/531,972 priority Critical patent/US8834931B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • the present invention relates to a pharmaceutical composition in dry powder form comprising tiotropium and mometasone and/or their pharmaceutically acceptable derivatives as active agents so as to be used in the treatment of respiratory tract diseases especially in asthma and chronic obstructive pulmonary disease (COPD), and the delivery of this pharmaceutical composition.
  • a pharmaceutical composition in dry powder form comprising tiotropium and mometasone and/or their pharmaceutically acceptable derivatives as active agents so as to be used in the treatment of respiratory tract diseases especially in asthma and chronic obstructive pulmonary disease (COPD), and the delivery of this pharmaceutical composition.
  • COPD chronic obstructive pulmonary disease
  • bronchia are the channels which function to distribute the inhaled air into the lung tissues.
  • stimulants such as allergen, infection, good and bad smell, smoke, genetic factors and exercise cause contractions in the airway muscles (bronchoconstruction) and/or excessive secretion in glands and results in contractions in the airway; hence, respiration gets more difficult as the inhaled air cannot be exhaled.
  • Corticosteroids which are used in the treatment of asthma and COPD are synthetic and strong anti-inflammatory drugs that are similar to natural corticosteroid hormones produced by adrenal glands. They prevent both the transcription of the inflammatory gene and the activation of the anti-inflammatory gene. They are known to be the most effective drug in the treatment of asthma.
  • Mometasone froate which was first described in the patent application US4472393, is a corticosteroid having the chemical name (1 l ,16a)-9,21-Dichloro-l 1 -hydroxy- 16- methyl-3,20 dioxopregna-l,4-diene-17-yl-2-furoate.
  • Corticosteroids are not preferred in acute asthma crises as they do not have rapid onset of action. Since inhaled corticosteroids may prevent growth in children, they are advised to be used in the lowest possible amount. Long-term use of corticosteroids may cause cataract and glaucoma. In addition, they may cause some serious side-effects such as osteoporosis, high cholesterol, edema, encepholalgia, weight gain, insomnia and some skin problems. 1 000012
  • Anticholinergics are the other active agents which are utilized in the treatment of respiratory disorders. Anticholinergics affect muscarinic receptors and prevent the obliteration in the bronchia due to excessive secretion. These drugs are categorized into two groups as long-acting and short-acting. Short-acting anticholinergics including ipratropium bromide and oxitropium bromide have an onset of action of 15 minutes and their duration of action is 6-8 hours. The long- acting anticholinergic agent is tiotropium.
  • Tiotropium having the chemical name (1R, 2R, 4S, 5S, 7S)-7-[(hydroxidi-2- thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo [3.3.1.0 2 ' 4 ] nonane, was first described in the patent application EP0418716. Tiotropium's onset of action is 20 minutes but its duration of action is 24 hours. Thus, it is enough to take it once a day. Xerostomia, blurred vision, glaucoma and dry cough are its side-effects.
  • combination drugs in the treatment of respiratory diseases such as asthma and COPD is very effective particularly in decreasing asthma attacks. It is possible that the severity or occurrence possibility of the abovementioned side effects decreases as the active substances that are used in combinations are more effective at lower doses compared to the active substances used alone.
  • the medicaments used in the formulations should be selected in a way to give the best combination and furthermore, they should be in the most stable form.
  • the compositions comprising them should be formulated in such a way that the composition is stable and also it reaches to the target area in the most efficient way.
  • the inventor has found that therapeutic benefits are obtained through the use of the combination comprising of tiotropium bromide with water content less than or equal to 2.5%, and mometasone furoate together in dry powder form for simultaneous or sequential administration in the prevention or treatment of respiratory diseases.
  • the amount of active agents used in the composition is carefully adjusted in order to prevent the side effects that might arise from these agents and it was seen that the adhesive force between the particles forming the composition is reduced and hence, the amount of inhaled particles and the efficacy of the formulation increases in addition to observing minimum side effects, when tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate present in the composition is used in an amount such that the ratio of tiotropium bromide with water content less than or equal to 2.5% to mometasone furoate is in the range of 1 :3 to 1 :40 by weight.
  • the particle size of the agents should be adjusted. Although large particle size provides ease in the manufacture of the dry powder, it may accumulate in throat and lead to insufficient intake of the medicament. Very fine particles, on the other hand, may reach the lungs. However, they might not have a good flow property, which causes problems in providing dose accuracy in turn. To prevent these problems, the active agents should have an optimum average particle size. The inventors have found that tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate combination wherein the mean particle size of the active agents is in the range of 1.5 to 4.5 ⁇ reaches the lungs effectively and also no problems related to flow properties of the dry powder are observed.
  • mean particle size refers to particles wherein the particle size of 50% of the total number of particles is less than the average particle size.
  • the present invention is related to dry powder formulations comprising a combination of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate in dry powder form wherein tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate are present in the composition in an amount that the ratio of tiotropium bromide with water content less than or equal to 2.5% to mometasone furoate is in the range of 1 :3 to 1 :40 by weight and wherein the mean particle size of the active agents (i.e.
  • tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate is in the range of 1.5 to 4.5 ⁇ .
  • the drug comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate may also contain effective amounts of excipients and/or additional agents apart from active agents.
  • the dry powder formulation comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate is transmitted to the patient in dry powder form.
  • Said dry powder formulations also contain some physiologically acceptable excipients along with the active agent. These excipients can be monosaccharides (glucose, etc.), disaccharides (lactose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorbitol, mannitol, xylitol, etc.), salts (sodium chloride, calcium carbonate, etc.) or a mixture thereof.
  • excipients can be monosaccharides (glucose, etc.), disaccharides (lactose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorb
  • compositions according to present invention in other words in compositions comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate in dry powder form wherein the mean particle size of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate is in the range of 1.5 to 4.5 ⁇ and wherein tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate are present in the composition in an amount that the ratio of tiotropium bromide with water content less than or equal to 2.5% to mometasone furoate is in the range of 1 :3 to 1 :40 by weight, using lactose as the one and only carrier provides optimum homogeneity and flow properties to the dry powder and this way dose accuracy is maintained.
  • lactose is used as the one and only carrier in dry powder formulations comprising combinations of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate in dry powder form.
  • lactose plays an important role in delivery of the medicament to the target area, i.e. lungs, effectively in compositions according to present invention. It was found that when lactose having a mean particle size less than or equal to 100 ⁇ is used in compositions comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate in dry powder form wherein the mean particle size of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate is in the range of 1.5 to 4.5 ⁇ and wherein said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively, the adhesive forces present between the lactose particles and the active agents having a mean particle size in the range of 1.5 to 4.5 ⁇ are minimized and thus, an effective inhalation of the active agents takes place.
  • the present invention provides a composition comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate in dry powder form wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier.
  • Lactose which has a mean particle size less than 100 ⁇ is preferably used as a mixture of particles which have two different mean particle sizes. Accordingly, lactose which has a mean particle size less than 100 ⁇ can be present as a mixture of particles having a mean particle size less than 10 ⁇ (finer) and particles having a mean particle size in the range of 10 ⁇ to 100 ⁇ (coarser). The inventors have observed that when lactose which has two different mean particle sizes is used, the adhesive force between the active agents and lactose is even less.
  • the ratio between the finer lactose particles which have a mean particle size less than 10 ⁇ and the coarser lactose particles which have a mean particle size in the range of 10 ⁇ to 100 ⁇ is in the range of 20:80% and 40:60% by weight.
  • the amount of pharmaceutically acceptable carrier is preferably in the range of 0-50 mg.
  • the finer lactose particles have a mean particle size less than 10 ⁇ , preferably between 2 ⁇ and 8 ⁇ and the coarser lactose particles have a mean particle size less than 100 ⁇ , preferably between 30 ⁇ and 80 ⁇ .
  • the medicament composition of the present invention is in dry powder form and it is inhaled via dry powder inhalers. Accordingly, the medicament can be inhaled from a reservoir containing dry powder, a blister pack in which many blisters are placed in an order or a capsule. Among these, the inhalers that enable the intake of a single dose in an accurate manner were found to give the best results. This condition is provided by the dosage forms wherein each dose of the medicament is stored in a single unit of dosage form. Accordingly, the medicament combination according to the present invention is stored in blister packs consisting of blisters or capsules and is inhaled via dry powder inhalation devices where blisters or capsules are used.
  • the inventor has surprisingly found that administering the dry power drug comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier as stored in a blister pack or capsule via a dry powder inhaler in order to prevent and treat respiratory diseases provides the transmission of the exact and the effective dose to the target area and elimination and/or alleviation of the known side effects of the therapeutic agents. Hence, maximum therapeutic benefit is provided due to the efficacy of the transmission method.
  • the present invention provides a dry powder drug comprising the combination of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and 11 000012
  • lactose which has mean particle size less than 100 ⁇ is used as carrier which realizes a simultaneous inhalation from the blister pack or capsule that can guarantee a single dose intake at once in order to achieve dose sufficiency.
  • the present invention provides inhalation of the dry powder drug comprising the combination of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier via a simple, low cost, trustable dry powder inhaler.
  • the present invention provides a drug that provides to realize the use of a composition comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier as stored together in a peelable blister or pierceable capsule pack in the treatment of respiratory diseases such as asthma and COPD.
  • the inventors have found that by storing the dry powder medicament pertaining to the present invention in blister packs comprising blisters and capsules which have the specified properties pertaining to the present invention; • equal dose intake is provided in each use as the dry powder formulation is filled into the blisters or capsules with a good dosage accuracy in the factory after the manufacture,
  • the drug is transmitted to the target area, which is the lungs, without absorbing moisture as the blister or capsule pertaining to the present invention is peeled/torn/pierced immediately before use,
  • devices containing blisters or capsules provide ease of use to the patients as they are small in size resulting from the fact that they work with simple mechanical components compared to other devices.
  • the present invention relates to a delivery method of a drug composition
  • a drug composition comprising a composition of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier which is particularly used in the treatment of people suffering respiratory diseases such as asthma, COPD and allergic rhinitis, as stored in a blister or capsule package via a dry powder inhaler.
  • the piercing components which exist in the device to prepare the dry powder drug carried in a capsule for inhalation, pierce the capsule when the device is triggered and the dry powder drug kept in the capsule becomes ready for inhalation. After the inhalation is completed, the empty capsule is ejected from the device and a new capsule is placed immediately before the following inhalation takes place.
  • the capsule package which is preferred to be used in scope of the present invention, consists of two intertwining parts.
  • the inventors have found that the ideal inhalation conditions are achieved when the volume of the capsule, which comprises the dry powder drug comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier mometasone furoate, is in the range of 0.1 to 0.52 ml, preferably in the range of 0.1 to 0.45 ml, more preferably in the range of 0.15 to 0.42 ml.
  • the capsule that is used to store and transmit the combination comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier is characterized in having a cavity volume in the range of 0.1 to 0.52 ml, preferably 0.1 to 0.45 ml, more preferably in the range of 0.15 to 0.42 ml.
  • the capsule package which has high protection against moisture and other negative external factors has a moisture rate between 10%-20%, preferably 15%-20%.
  • both the active composition is protected from external factors and the probability of moisture arising from the capsule's own structure are prevented.
  • the most effective transmission to the patient is enabled by preventing the agglomeration of the dry powder.
  • the capsule which is preferred to be used in scope of the present invention, can be made of a substance chosen from a group including gelatine, chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers as well as consisting intertwined upper and lower parts. These upper and lower parts of said capsule can be produced of identical or different materials.
  • the capsule material can be selected from, but not limited to, a group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose.
  • the capsule material can be selected from, but not limited to, a group including polyethylene, polyetheleneteraphtalate, polycarbonate or polypropylene.
  • capsule material used in the present invention is gelatine
  • additional agents such as polyethylene glycol, sorbitol, glycerol, propylene glycol, polyethylene oxide - polypropylene oxide block copolymers and/or other polyalcohols or polyethers at different molecular weights can be added into it.
  • the present invention is characterized in that the capsule cavity used to provide an effective inhalation of the dry powder medicament is filled up to 0.01% to 25% of its total volume, preferably 0.1 to 20% of its total volume, more preferably 0.5 to 17% of its total volume.
  • the present invention comprises dry powder formulations containing tiotropium and mometasone furoate and/or pharmaceutically acceptable derivatives and their administration to patients from a capsule having a total cavity volume in the range of 0.1 to 0.52 ml and wherein the capsule cavity is filled up to 0.01% to 25% of the total volume, via a dry powder inhaler.
  • the capsule pack pertaining to the present invention can be in any color or shape as long as it has the properties described above.
  • the capsule or the blister pack which comprises the formulation pertaining to the present invention, can be used with any dry powder inhalation device, for example with devices as described in the patent applications numbered TR2008/03522, TR2008/03523, TR2010/03091 , TR2010/04311.
  • blister packs can be used as the package for the dry powder medicament according to the invention.
  • Blister packages can be a) torn b) pierced or c) peeled to be opened according to the structure of the device and the blister.
  • the inventors have found that it is difficult to use dry powder inhalers which contain pierceable or tearable blister packs for patients as these devices require additional components which increase the size, volume and the complexity of the device.
  • the amount of uninhaled dry powder formulation remaining in the blister cavity increases due to the roughness resulting from being torn and therefore, the rate of utilization from the present dry powder formulation decreases in tearable blisters.
  • the amount of dry powder remaining in the blister cavity decreases as said dry powder combination is transmitted much more effectively with a high discharge capacity in the case that peelable blisters are used.
  • the dry powder medicament pertaining to the present invention can be carried in peelable blister packages.
  • Blister packs are comprised of orderly placed blisters each of which contains minimally one dose of the dry powder drug.
  • the blister pack or one of the blisters in the pack is peeled and the drug in dry powder form is prepared for inhalation.
  • the cavity volume of the blisters that are arranged side by side in a certain order on the blister pack which provides to carry and store the drug in dry powder from is 17 to 30 mm 3 , preferably 18 to 23 mm 3 , most preferably 19 to 21 mm 3 .
  • the cavity volume of the blisters pertaining to the present invention which provide to transmit and store the dry powder drug comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier is in the range of 17-30 mm 3 , preferably in the range of 18-23 mm 3 , most preferably in the range of 19-21 mm 3 and each blister cavity having the volume described above is filled up to 25-100 %, preferably up to 70-100 %, most preferably up to 90-100 % of said volume in order to meet the specified needs for an effective inhalation.
  • the lid and the base sheets of said blister pack constituted by the blisters having the specified properties, in which the drug in dry powder form pertaining to the present invention is stored, are closed very tightly by any suitable method to provide impermeability.
  • the lid and the base sheets constituting the blister package consist of several layers.
  • Polymeric layers, aluminum foil and preferably Aclar® fluoropoylmer film are among the layers that form the lid and the base sheet.
  • Aclar® fluoropolymer film is a polymeric film which is used in blister packs and provides excellent moisture barrier. This chemically inert polymeric film does not cause any change in the taste of the formulation when it is in contact with the dry powder formulation. In addition, it easily constitutes a layered structure with the other polymeric layers which are composed of various polymers. It is appropriate to be transacted with heat.
  • desiccant agents are added to the polymeric layers to preserve the stability of the dry powder formulation stored in blisters that are arranged in an order on the blister package. Silica gel, zeolite, alumina, bauxite, anhydrous calcium sulfate, activated carbon and clay which have the property of water absorption can be given as examples to desiccant agents.
  • the thickness of the aluminum foil that is used in the lid and the base sheets of the blister pack is chosen to be in the range of 10 to 40 ⁇ , preferably of 15 to 30 ⁇ .
  • the polymeric layers in the lid and the base sheets of the blister pack mentioned in the present invention are composed of the same or different polymers.
  • the thickness of these polymeric layers varies according to the type of the polymeric substance used and its properties. Therefore, the thickness of the polymeric layer varies in the range of 15-60 ⁇ , preferably of 20-35 ⁇ depending on the type of the polymer used.
  • the blisters which constitute the blister pack in which the dry powder drug pertaining to the present invention is stored can be in any shape as long as they have the properties described above.
  • the dry powder particles Due to the electrostatic interactions between the dry powder particles and the inside layer of the blister cavity or the capsule material which is in contact with the dry powder formulation, the dry powder particles mainly adhere to said inside layer of the blister cavity or said capsule material. Since some uninhaled dry powder formulation is remained in the blister cavity or the capsule during inhalation, sufficient amount of the dry powder formulation for an effective therapy cannot reach to the lungs. Therefore, the inside layer of the blister cavity or the capsule material that is in contact with the dry powder formulation is an antistatic material.
  • antistatic material refers to a material which eliminates the buildup of static electricity.
  • the antistatic material used herein encloses a material which is antistatic itself or which is not antistatic itself but contains antistatic agent(s).
  • an antistatic agent is used for treatment of the layer or their surfaces in order to reduce or eliminate the buildup of static electricity generally caused by the triboelectric effect (charge generation by friction). Its role is to make the surface or the material itself slightly conductive, either by being conductive itself, or by absorbing moisture from the air. Therefore, some humectants can be used.
  • the molecules of an antistatic agent often have both hydrophilic and hydrophobic areas similar to those of a surfactant. The hydrophobic side interacts with the surface of the material while the hydrophilic side interacts with the air moisture and binds the water molecules.
  • Antistatic agents are basically classified into two groups: internal antistatic agents and external antistatic agents. Internal antistatic agents are designed to be mixed directly into the material whereas external antistatic agents are applied to the surface.
  • Antistatic agents used within the scope of the invention are selected from a group comprising long-chain aliphatic amines (optionally ethoxylated) and amides, glycerol monostearate (GMS), saturated fatty acids, (poly)unsaturated fatty acids, quaternary ammonium salts (e.g., behentrimonium chloride or cocamidopropyl betaine), sulfonated organic compounds, esters of phosphoric acid, polyethylene glycol esters, polyols and combinations thereof. Also, some commercially available antistatic additives such as OnCapTM, Larostat ®, EntiraTM, Nourymix®, can be used as antistatic agents. It is also possible to use conductive polymers like PEDOT:PSS and conducting polymer nanofibers, particularly polyaniline nanofibers.
  • the present invention provides a medicament comprising a composition of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier as stored in capsules or blisters wherein the inside layer of the blister cavity or the capsule material that is in contact with the dry powder formulation is an antistatic material.
  • tiotropium bromide with water content less than or equal to 2.5% which is one of the active agents of the medicament formulation comprising the active agent combination, includes its pharmaceutically acceptable solvates, polymorphs, crystal forms, amorphous forms and/or combinations thereof.
  • mometasone furoate which is one of the active agents of the medicament formulation comprising the active agent combination, includes its pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, free base, polymorphs, crystal forms, amorphous forms and/or combinations thereof.
  • the amount of tiotropium bromide with water content less than or equal to 2.5% is in the range of 1 to 40 ⁇ g per dose, preferably in the range of 1 to 30 g per dose in the medicament formulation in dry powder form comprising the combination of tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate and/or pharmaceutically acceptable derivatives thereof.
  • the dry powder drug comprising tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate wherein;
  • said active agents are present in the composition with the ratio of 1 :3 to 1 :40 respectively and
  • lactose which has a mean particle size less than 100 ⁇ is used as carrier as stored in capsules or blisters wherein the inside layer of the blister cavity or the capsule material that is in contact with the dry powder formulation is an antistatic material according to the present invention can be used in the treatment of several respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
  • COPD chronic obstructive pulmonary disease
  • these respiratory diseases can be, but not limited to, allergic and non-allergic asthma at any phases, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), intensifying of airways hyperactivity, bronchiectasis, chronic obstructive pulmonary, airways or lung disease including amphizem and chronic bronchitis, pneumokoniosis, aluminosis, antracosis, asbetosis, calicosis, phytilosis, ciderosis, silicosis, tabacosis, bissnosizn.
  • This treatment can be prophylactic or symptomatic.
  • said composition is preferably used for symptomatic treatment of asthma, COPD and allergic rhinitis.
  • a method for preparing the pharmaceutical composition according to the present invention comprises micronizing tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate, preferably by air jet mill, mixing micronized tiotropium bromide with water content less than or equal to 2.5% and mometasone furoate with lactose, then blending the composition to obtain a homogeneous dry powder mixture, and then filling the obtained dry powder mixture into capsules or blisters.
  • the dry powder formulation which is appropriate for a gelatine capsule used in the capsule inhalator comprises 12 parts of tiotropium bromide with water content less than or equal to 2.5% and 200 parts of mometasone furoate that are micronized by an air jet mill to obtain micronized particles with a mean particle size of 1.5 to 4.5 ⁇ ⁇ ⁇ ; and then the micronized particles are mixed with 4500 parts of lactose as carrier which have a mean particle size below ⁇ .
  • Tiotropium bromide bromide with water content less than or equal to 2.5% given in this example comprises its all pharmaceutically acceptable solvates, polymorphs, amorphous forms and crystalline forms.
  • Mometasone furoate given in this example comprises its all pharmaceutically acceptable solvates, hydrates and/or enantiomers, polymorphs, amorphous and crystal forms.
  • Lactose, which is used as carrier, can optionally be added in a higher or a lower amount.
  • the capsule described in the example is made of gelatine and it can optionally be made of chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers and the inside of the capsule is coated with an antistatic material.
  • a dry powder formulation which is suitable to be stored in blisters so as to be used in a multiple dosing inhalator comprises 18 parts of tiotropium bromide with water content less than or equal to 2.5% and 400 parts of mometasone furoate that are micronized by an air jet mill to obtain particles with a mean particle size of 1.5-4.5 ⁇ , and then the micronized particles are mixed with 10200 pieces of lactose having a mean particle size of less than 100 ⁇ as a carrier.
  • Tiotropium bromide with water content less than or equal to 2.5% given in this example comprises its all pharmaceutically acceptable solvates, polymorphs, amorphous forms and crystalline forms.
  • Mometasone furoate given in this example comprises its all pharmaceutically acceptable solvates, hydrates and/or enantiomers, polymorphs, amorphous and crystal forms. Lactose, which is used as carrier, can optionally be added in a higher or a lower amount.
  • the example can be repeated by replacing the amounts in Example 20 with the amounts given in the table below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques sous forme de poudre sèche comprenant du tiotropium et du furoate de mométasone et/ou leurs dérivés acceptables au plan pharmaceutique en tant que principes actifs, ainsi que des formes de capsules et d'emballage-coques contenant ces compositions pharmaceutiques afin d'être utilisées dans le traitement de maladies des voies respiratoires.
PCT/TR2011/000012 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone WO2011093810A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00619A TR201000619A2 (tr) 2010-01-28 2010-01-28 Tiotropium ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.
TR2010/00619 2010-01-28
TR2010/00730A TR201000730A2 (tr) 2010-02-02 2010-02-02 Tiotropyum ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.
TR2010/00730 2010-02-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000014 Continuation-In-Part WO2011093812A2 (fr) 2009-12-25 2011-01-28 Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000011 Continuation-In-Part WO2011093809A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide

Publications (2)

Publication Number Publication Date
WO2011093810A2 true WO2011093810A2 (fr) 2011-08-04
WO2011093810A3 WO2011093810A3 (fr) 2012-02-23

Family

ID=43899579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000012 WO2011093810A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone

Country Status (1)

Country Link
WO (1) WO2011093810A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107951893A (zh) * 2016-10-18 2018-04-24 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472393A (en) 1981-02-02 1984-09-18 Schering Corporation 3,20-Dioxo-1,4-pregnadiene-17α-ol 17-aromatic heterocycle carboxylates
EP0418716A1 (fr) 1989-09-16 1991-03-27 Boehringer Ingelheim Kg Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires, leur préparation et l'utilisation de ces composés
TR200803522A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Kolay kullanımlı inhalasyon cihazı.
TR200803523A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Şerit ambalaj içeren düzenek

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
TR200909793A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472393A (en) 1981-02-02 1984-09-18 Schering Corporation 3,20-Dioxo-1,4-pregnadiene-17α-ol 17-aromatic heterocycle carboxylates
EP0418716A1 (fr) 1989-09-16 1991-03-27 Boehringer Ingelheim Kg Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires, leur préparation et l'utilisation de ces composés
TR200803522A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Kolay kullanımlı inhalasyon cihazı.
TR200803523A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Şerit ambalaj içeren düzenek

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107951893A (zh) * 2016-10-18 2018-04-24 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物
CN107951893B (zh) * 2016-10-18 2022-04-26 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物

Also Published As

Publication number Publication date
WO2011093810A3 (fr) 2012-02-23

Similar Documents

Publication Publication Date Title
EP2528585B1 (fr) Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide
EP2528600B1 (fr) Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone
EP2528596B1 (fr) Composition sous forme de poudre sèche pour administration par inhalation comprenant une combinaison de bromure de tiotropium, de xynafoate de salmeterol et de propionate de fluticasone.
EP2533777B1 (fr) Compositions pharmaceutiques contenant de la fluticasone, du tiotropium et du cromoglycate de sodium
WO2011093819A2 (fr) Nouvelle composition pharmaceutique combinée comprenant du tiotropium
WO2011093820A2 (fr) Composition pharmaceutique combinée comprenant du tiotropium
WO2011093815A2 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
WO2011093818A2 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
WO2011093811A2 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
EP2480203B1 (fr) Formulation de poudre sèche de tiotropium contenue dans une bande alvéolée thermoformée
WO2011093812A2 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
EP2528597B1 (fr) Composition sous form de poudre sèche comprenant une combinaison de bromure de tiotropium, fumarate de formoterol et de furoate de mometasone
WO2011093814A2 (fr) Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2013109219A1 (fr) Formulations en poudre sèche comprenant du tiotropium et du carmotérol
WO2011093810A2 (fr) Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone
EP2804585A1 (fr) Formulations en poudre sèche comprenant du tiotropium, du formotérol et du budésonide
WO2011093809A2 (fr) Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide
EP2515845B1 (fr) Formulation de poudre sèche comprenant du tiotropium, du formoterol et un derive d'acide cromoglicine
EP2515848A1 (fr) Combinaison de poudre sèche constituée de tiotropium, d'un corticostéroïde et d'un dérivé d'acide cromoglicique
WO2011049539A1 (fr) Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil
EP2480202A2 (fr) Bande alvéolée thermoformée contenant une combinaison qui renferme du tiotropium
EP2804584A1 (fr) Formulations en poudre sèche comprenant du carmotérol et de la ciclésonide
WO2011049538A2 (fr) Composition pharmaceutique sous forme de poudre sèche
EP2804589A1 (fr) Formulations pharmaceutiques comprenant de l'aztréonam
WO2013109207A1 (fr) Formulations de poudre sèche comprenant de la mométasone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11707730

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11707730

Country of ref document: EP

Kind code of ref document: A2